Volume - 13 | Issue-1
Volume - 13 | Issue-1
Volume - 13 | Issue-1
Volume - 13 | Issue-1
Volume - 13 | Issue-1
Low solubility and permeability of raolazine (RZ) result in restricted and changeable bioavailability; less stability makes it challenging to create stable aqueous liquid formulations; low dosage makes it challenging to achieve homogenous medication distribution. This study set out to determine whether a plan based on the creation of nanostructured lipid carriers (NLC) as a novel oral formulation of RZ with enhanced therapeutic efficacy was effective. Solid and liquid lipids, as well as surfactant produced by hot homogenization and ultrasonication, were used to design and create nanostructured lipid carriers (NLCs). An strategy based on quality by design (QbD) was used to optimise the formulation. Through the use of a central composite design, three variables—total lipid concentration, surfactant concentration